Blueberry NFT CO., LTD. Overview
Billions Co., Ltd. is a small-cap KOSDAQ hybrid. A 53-year-old latex-rubber hygiene manufacturer, historically Korea's leading domestic condom maker under the Unidus name, sits alongside an entertainment business built through acquisitions from 2023. That business manages actors and singers, produces music and concerts, and, through its subsidiary Billions Plus, produces drama. Since 2017 the listed shell has passed through biotech, pharma-holding, NFT and entertainment identities. Each pivot came with a change of control or a new theme. Since May 2024 the company has sat inside the Humasis–Mirae I&G group, which Stella PE took over in March 2026. Revenue is about KRW 25 billion a year and has carried operating losses for at least five consecutive years. Accumulated deficits approach KRW 100 billion. The company has relied on repeated rights offerings, convertible bonds, a par-value reduction and two share consolidations to stay solvent and listed. Its newest stated direction is advanced manufacturing and aerospace supply-chain investment.
What the company does today. Third-party summaries of the company's filings describe two operating pillars:
-
Healthcare/hygiene rubber products. Manufacture, wholesale, retail and export of condoms, rubber finger cots (고무골무) and medical gloves. The registered industry classification remains "rubber apparel and other sanitary unvulcanized rubber products manufacturing." The condom brand currently catalogued is Long Love (롱러브). In the 2020–2022 period the company also sold KF-94 masks and distributed vitamins, placenta products and health foods. Investing.com's profile still lists these lines, but they appear to date from the Kyungnam Biopharma era.
-
Entertainment. Artist management of actors and singers, album planning and music production, concert promotion, and film/drama production. Production runs through the subsidiary Billions Plus, which produced the 2025 Coupang Play series Newtopia. StockHub's summary of the filings lists the content activities as planning, developing and supplying content, producing and managing drama and film in several genres, artist management, concert planning, and music/album distribution and marketing.
The company's own description. The latest annual-report wording could not be retrieved verbatim. In November 2025, when merging the subsidiary XYG Studio, management framed the goal as evolving from a manufacturing-based listed company into an integrated IP, music and video production company. The merger brought planning, casting, music and production under one corporate roof (Money Today, 28 Nov 2025).
Business and revenue model.
Hygiene products: manufactured-product sales, B2C and B2B, with a domestic retail and export history.
Entertainment: management-fee and commission revenue from artist activity (advertising, drama/film appearances), album and merchandise sales, concert and tour revenue, and production revenue from content sold or licensed to OTT platforms.
Product vs. service mix: not disclosed. Separate-basis cost of sales was about 80% of revenue in FY2025 (179.5 of 225.6). That is consistent with a revenue base dominated by low-margin pass-through items such as artist settlements, merchandise and goods, rather than high-margin licensing.
- No subscription or licensing revenue streams of significance have been disclosed.
Value-chain position.
-
In hygiene products, Billions is an upstream/midstream manufacturer. It converts latex into finished goods at its Jeungpyeong site.
-
In entertainment, it is a mid-tier talent agency, with a nascent in-house production arm and concert/album capability. It has no platform or distribution ownership.
Customer types and end-markets. Domestic Korean consumers and retailers, plus public-sector buyers, for hygiene products. Historical exports went to the WHO and UNFPA (1998). Korean broadcasters, OTT platforms (Coupang Play, Netflix, Disney+, Tving), advertisers and concert audiences in Korea and Asia for entertainment. Management has signalled an intended Japan music partnership (Nov 2025).
Independent characterization. Billions is best understood as a restructuring vehicle inside a listed-company group, not as a focused operating company. Its strategic narrative has changed four times in nine years (biotech → pharma holding → NFT → entertainment → aerospace investing). Its largest balance-sheet items are financial: equity-method stakes, convertible bonds and cash from recent placements. They are not operating assets. The entertainment roster is real and recognisable, and the hygiene business provides a modest revenue floor. But the company has not demonstrated that either business can cover interest and overhead.
Strategy
-
Integrated entertainment company. The company states it wants to become an end-to-end IP company spanning planning, casting, music, video production and performance. The vehicle is the absorption of XYG Studio (Nov 2025) plus the production subsidiary Billions Plus. The aim is to run planning–casting–production as one process targeting global OTT platforms (Money Today, Nov 2025).
-
Premium vocalist music and concert platform. The company is building around established K-pop vocalists (Kim Sung-kyu, Nam Woo-hyun, Jung Eun-ji, Kim Yong-jun, Yoon Ji-sung). It plans directly promoted solo concerts, overseas tours, OSTs and project albums, and a Japanese record-label partnership.
-
Aggressive roster expansion. Management has stated an intention to grow management scale through aggressive artist recruitment. 2026 signings include Kim Ha-neul (2025), Yoo Ah-in, Lee Jung-jin and Go Won-hee.
-
Advanced manufacturing / aerospace. The Tris stake (May 2026) was framed as a strategic step toward advanced manufacturing and global aerospace investment and M&A, not merely a financial investment (Asia Economy; Money Today, 27 May 2026). The parent Humasis separately added semiconductor materials and equipment to its business purposes in March 2026.
-
Capital-structure repair and listing maintenance. Measures include the par reduction (2025), equity raises (2025, 2026) and two 5:1 consolidations (2026). The consolidations were explicitly linked to the Korea Exchange's planned delisting rule for stocks persistently priced below KRW 1,000, effective from July 2026 (The Bell, Apr 2026; Dailypharm, Mar 2026).
Initiatives announced in the last 24 months.
Sustainability/ESG commitments, cost programs, medium-term financial targets or guidance: none publicly disclosed.
Products & Services
Healthcare / Hygiene Rubber Products
| Product / brand | Description | Target customer | Launch / status | Pricing | Source |
|---|---|---|---|---|---|
| Long Love (롱러브) condoms | Latex condom brand currently catalogued for the company | Consumers via retail/online | Active (year not disclosed) | — | THE VC |
| Historical condom brands ("Million," "Ecstasy," Unidus range) | Domestic condom brands of the 1990s–2000s | Consumers; WHO/UNFPA export | Legacy | — | Wikipedia |
| Rubber finger cots (고무골무) | Protective latex finger covers | Industrial and medical buyers | Active | — | Digital Today (company description) |
| Medical / surgical gloves | Latex gloves; KS-marked since 1988 | Hospitals, public procurement | Active | — | Digital Today; Wikipedia |
| KF-94 masks | Health masks (COVID-era) | Consumers, public sector | 2020–2022; current status not disclosed | — | Investing.com; THE VC tech keywords |
| Vitamins, placenta products, health foods | Distribution of Kyungnam Pharm-related goods | Consumers | Historical; status not disclosed | — | Investing.com profile |
Entertainment — Artist Management (selected roster, per company website and press)
| Artist group | Named artists | Joined | Source |
|---|---|---|---|
| Actors (legacy Star Village) | Park Myung-shin, Jung Suk-yong, Jo Hee-bong | Mar 2023 | Wikipedia |
| Actors (legacy J-Flex) | Lee Jun-young, Ko Chang-seok, Han Sang-jin, Kwon So-hyun, Kim Kang-min, Choi Ji-hye | Jul 2023 | Wikipedia |
| Actors (legacy XYG Studio) | Jo Bo-ah, Jung Sung-il, Jang Yoon-ju, Geum Hae-na, Kim Jae-cheol, Ji Hye-won | Merged Nov 2025 | Money Today; Wikipedia |
| Actors signed 2023–2026 | Song Ji-woo, Lee Kyu-han, Wang Ji-won, Lee Il-jun, Lee Yoo-jun, Oh Se-young, Heo Sung-tae, Son Hyun-joo, Kim Ha-neul, Yu Ha-jin, Lee Ha-eun, Park Wan-hyeong, Choi Moo-sung, Yoo Ah-in (Aug 2026), Lee Jung-jin (Sep 2026), Go Won-hee (Sep 2026) | Various | Wikipedia; IS Plus; TV Report |
| Singers / vocalists | Kim Sung-kyu (INFINITE), Nam Woo-hyun (INFINITE), Jung Eun-ji (Apink), Kim Yong-jun (SG Wannabe), Yoon Ji-sung (ex-Wanna One) | 2024–2025 | Money Today; Wikipedia |
Entertainment — Music, Concerts & Merchandise
| Offering | Description | Date | Source |
|---|---|---|---|
| Lee Jun-young, Last Dance | Mini-album | 2,025 | Wikipedia |
| Jung Eun-ji, Summer, I | 5th mini-album (first in ~6 years) and solo concert | 11 Aug 2026 | THE VC news feed |
| Nam Woo-hyun, 2X8 | 2nd full-length album, 16 tracks, title track "DEVIL" | 14 Oct 2026 | THE VC news feed (TenAsia; MHN Sports) |
| Nam Woo-hyun, 식목일VI – EVER GREEN | Seoul solo concert and Asia tour (10th solo anniversary) | Q4 2026 | MHN Sports via THE VC |
| Lee Jun-young 2027–2028 season's greetings | Two-year merchandise product | Announced Oct 2026 | TenAsia via THE VC |
| Japan music project | Planned partnership with a major Japanese record company | Stated as intended within 2025; completion not confirmed | Money Today (28 Nov 2025) |
Entertainment — Content Production (Billions Plus)
| Title | Format | Platform | Year | Notes | Source |
|---|---|---|---|---|---|
| Newtopia | Drama series (Park Jung-min lead) | Coupang Play | 2,025 | Ranked highly on Coupang's global OTT index per company | Money Today; Wikipedia |
Discontinued / Dormant Lines (Biogenetics and Blueberry NFT eras)
| Line | Description | Period | Current status | Source |
|---|---|---|---|---|
| ASLAN-001 (varlitinib), ASLAN-003 | Korean rights to oncology candidates | 2,019 | No disclosed development activity since 2021 | Edaily |
| Baseball player NFT cards | KPBPA publicity rights | 2021–2022 | — | Blockmedia |
| ELVN K League NFT platform | Goal and highlight NFTs | Launched Sep 2022 | — | Dealsite |
| V-League volleyball NFTs | Sold on OpenSea; Korbit marketplace MOU | 2,022 | — | The Value News |
| STAN by B | Art-NFT marketplace and gallery | 2,021 | — | Asia Economy |
| Pixelground | P2E game with Meta Kongz and Doge Sound Club NFTs | 2,022 | — | Dealsite |
| NFT PASS | Ticket NFTs for Ultra Korea 2022 and the Jarasum Jazz Festival | 2,022 | — | TokenPost |
Financial Narrative
Income Statement — Consolidated (KRW 100M)
Source: OpenDART via Bullstory (consolidated). Margins computed. FY2025 net loss reported as KRW 74 (100M) by The Bell (Apr 2026), which differs by rounding.
Revenue CAGR FY2021–FY2025: −0.5% a year (258 → 253). Revenue has swung with consolidation-perimeter changes rather than organic growth.
Income Statement — Separate (Parent-Only) and TTM (KRW 100M)
The columns below are trailing-twelve-month (TTM) windows ending on the stated quarter. "TTM Dec-2025" equals the full FY2025.
Source: DataHero/ValueLine, separate (parent-only) TTM figures, updated through 2Q 2026. Margins computed. Derivative losses at TTM Jun-2025 and Sep-2025 shown as 0 where the source reported N/A.
Derived EBITDA (operating income + depreciation in cost of sales and SG&A; separate basis):
-
FY2025: −2.8 + 2.7 + 9.8 = KRW 9.7 (100M)
-
TTM Jun-2026: 0.4 + 3.1 + 9.5 = KRW 13.0 (100M)
These are analyst-derived figures, not company-reported.
Balance Sheet — Separate (Parent-Only), KRW 100M
The table covers FY2022–FY2025. The 1H 2026 values, as of 30 Jun 2026, are given in the commentary below because the table is limited to fiscal years.
Source: DataHero/ValueLine, separate basis. Total debt, net debt and working capital are computed by the analyst.
1H 2026 (30 Jun 2026, separate).
-
Total assets KRW 686.4 (100M); current assets 436.0.
-
Cash 242.8 plus short-term financial assets 57.8.
-
Short-term borrowings 24.9; short-term bonds 100.9; total debt ~125.8; net cash ~KRW 174.8 (100M) including short-term financial assets.
-
Total liabilities 230.6; equity 455.8.
-
Retained deficit −945.5; capital surplus 1,228.1.
Consolidated balance-sheet footnote data. Total assets: 1,723.4 (FY2022), 1,996.1 (FY2023), 488.4 (FY2024). Total liabilities: 657.1 / 1,071.5 / 268.2. Equity: 282.3 / 160.0 / 220.6 (DataHero/ValueLine, "equity-method applied" footnote series; the FY2024 figures match media reports of the consolidated FY2024 balance sheet). The Bell reports a consolidated accumulated deficit of KRW 974 (100M) at end-FY2025.
Cash Flow
Source: OpenDART via Bullstory (OCF). PP&E is small (separate KRW 40.6 (100M) at FY2025), which implies capex is minor.
Equity financing — the company's real "cash flow".
Ratios
Computed from DataHero/ValueLine separate balance-sheet data. THE VC independently reports a FY2025 current ratio of 91.9%, which agrees.
Single-year and TTM ratios (separate basis).
ROE FY2025: −69.4 / avg equity 236.5 = −29.3%. ValueLine reports trailing ROE of −41.5% (Oct 2026).
ROA FY2025: −69.4 / avg assets 477.7 = −14.5%.
Interest coverage FY2025: operating income −2.8 / interest 25.6 = negative (−0.1x). On derived EBITDA: 9.7 / 25.6 = 0.38x.
Net debt / EBITDA FY2025: 7.2 / 9.7 ≈ 0.7x. Net cash at 1H 2026.
Asset turnover FY2025: 225.6 / 477.7 = 0.47x.
Current ratio 1H 2026: 1.92x. D/E 1H 2026: 0.28x.
ROIC, cash conversion cycle: not computable from retrieved data; marked not disclosed.
Commentary — Trends, Inflections, Drivers
Revenue. Consolidated revenue has moved in a band of KRW 25–71 billion. The spikes come from acquisitions and changes in consolidation scope, not organic momentum: Kyungnam Pharm in FY2022, then entertainment subsidiaries in FY2024. On a separate basis, revenue fell from a TTM peak of 291.8 (Jun-2025) to 225.6 in FY2025, then recovered to 245.8 TTM to Jun-2026. That pattern is consistent with lumpy entertainment project revenue, such as album and concert cycles and drama delivery.
Operating profitability. Losses have narrowed: consolidated operating loss went from −56 (FY2021) to −8 (FY2025), and separate operating income was break-even on a TTM basis in 2026. This is the most constructive data point in the file. Gross margin on the separate basis is thin, at roughly 18–22%, which leaves little room to absorb SG&A of KRW 47–56 (100M).
Below-the-line losses dominate. In every year except FY2024, net loss vastly exceeds operating loss. The recurring drivers are:
-
Interest expense of ~KRW 25 (100M) a year, mostly on convertible bonds.
-
Equity-method losses of KRW 16–26 (100M) from associates, principally Kyungnam Pharm.
-
Impairments and other non-operating charges.
-
In 1H 2026, a KRW 149.9 (100M) derivative loss, consistent with fair-value remeasurement of CB conversion options after the share price fell and the conversion terms reset.
FY2024's positive net income of KRW 86 (100M) was a non-operating event. It should not be treated as recurring.
Balance sheet. The FY2023 low point (equity 132.8; D/E 1.7x) prompted:
-
the 2025 par-value reduction, which eliminated deficits against share capital and created a KRW 162.6 (100M) capital-reduction surplus;
-
two equity raises totalling ~KRW 21.6bn.
By June 2026 the parent held net cash and an equity base of KRW 455.8 (100M). However, this was funded largely by its own parent, Humasis, and accompanied by a cumulative 25:1 share consolidation.
Cash flow. Operating cash flow turned modestly positive (KRW 7 (100M)) in FY2024–FY2025 after three negative years. That is not sufficient to cover interest.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Activity | Status / notes | Source |
|---|---|---|---|---|
Billions Plus (빌리언스플러스) | Subsidiary | Film/drama production; produced Newtopia (Coupang Play, 2025) | Founded Mar 2012; CEO Kim Woo-jae; 4 employees (Jun 2026) | THE VC; Money Today |
XYG Studio | Former subsidiary | Actor management | Absorbed into parent, Nov 2025 | Money Today; Wikipedia |
Blade Music / Blade Creative / Blade Media | Former subsidiaries | Music, creative, media | Absorbed Jun 2024 | Wikipedia |
Star Village Entertainment | Former acquiree | Actor management | Acquired Jan 2023; merged Mar 2023 | Wikipedia |
J-Flex | Former acquiree | Actor management | Acquired Jul 2023; merged Sep 2023 | Wikipedia |
Blueberry Meta | Former subsidiary (NFT) | Sports NFT platforms (ELVN) | Current status not disclosed | Dealsite (2022) |
Kyungnam Pharm (경남제약) | Associate (largest shareholder at 19.84% as of Oct 2024) | OTC pharma and health supplements (Lemona) | Cross-holding: Kyungnam Pharm holds Billions convertible bonds | Daum/Asia Toyo (Oct 2024); Digital Today |
Tris (트리스) | Minority investment (3.97%) | Stainless/special-alloy pipe and tubes | Acquired May 2026 | Asia Economy |
Segment (As Described) Overview
| Segment (as described) | Contents | Products / services |
|---|---|---|
Healthcare / hygiene goods | Latex-rubber manufacturing at Jeungpyeong | Condoms (Long Love), rubber finger cots, medical gloves; historically masks |
Entertainment / content | Artist management, music and concerts, drama/film production | Actor and singer management, albums and season's-greetings merchandise, concerts and tours, OTT drama production (Billions Plus) |
Revenue by Segment (KRW) and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue consolidated (KRW 100M) | 258 | 706 | 290 | 417 | 253 |
Revenue YoY growth consolidated (%) | 0 | 173.6 | -58.9 | 43.8 | -39.3 |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue consolidated (KRW 100M) | 258 | 706 | 290 | 417 | 253 |
Operating income consolidated (KRW 100M) | -56 | -31 | -6 | -11 | -8 |
Net income consolidated (KRW 100M) | -318 | -247 | -308 | 86 | -73 |
Operating cash flow consolidated (KRW 100M) | -20 | -16 | -34 | 7 | 7 |
Operating margin consolidated (%) | -21.7 | -4.4 | -2.1 | -2.6 | -3.2 |
Net margin consolidated (%) | -123.3 | -35.0 | -106.2 | 20.6 | -28.9 |
Income Statement (KRW) and Margin Analysis (%) (TTM Jun-2025–TTM Jun-2026)
| Metric | TTM Jun-2025 | TTM Sep-2025 | TTM Dec-2025 | TTM Mar-2026 | TTM Jun-2026 |
|---|---|---|---|---|---|
Revenue separate (KRW 100M) | 291.8 | 277.8 | 225.6 | 256.5 | 245.8 |
Cost of sales separate (KRW 100M) | 238.5 | 228.6 | 179.5 | 204.4 | 192.0 |
Gross profit separate (KRW 100M) | 53.2 | 49.1 | 46.0 | 52.0 | 53.8 |
SG&A separate (KRW 100M) | 56.4 | 48.6 | 48.8 | 47.4 | 53.3 |
Operating income separate (KRW 100M) | -3.1 | 0.4 | -2.8 | 4.6 | 0.4 |
Interest expense separate (KRW 100M) | 24.3 | 25.1 | 25.6 | 25.5 | 24.3 |
Derivative losses separate (KRW 100M) | 0 | 0 | 4.8 | 4.8 | 149.9 |
Equity-method P&L separate (KRW 100M) | -16.8 | -15.6 | -18.8 | -17.1 | -25.6 |
Pre-tax income separate (KRW 100M) | -29.3 | -13.9 | -70.3 | -54.5 | -199.3 |
Net income separate (KRW 100M) | -28.0 | -12.9 | -69.4 | -53.8 | -189.0 |
Gross margin separate (%) | 18.2 | 17.7 | 20.4 | 20.3 | 21.9 |
Operating margin separate (%) | -1.1 | 0.1 | -1.2 | 1.8 | 0.2 |
EPS separate adjusted for 25:1 consolidation (KRW) | -1,571.2 | -644.4 | -2,706.4 | -1,800.3 | -4,187.1 |
Balance Sheet (KRW)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets separate (KRW 100M) | 471.9 | 457.7 | 475.6 | 479.7 |
Current assets separate (KRW 100M) | 130.7 | 180.3 | 132.1 | 206.3 |
Cash and equivalents separate (KRW 100M) | 44.6 | 80.4 | 58.2 | 131.8 |
Short-term borrowings separate (KRW 100M) | 0 | 0 | 10.0 | 24.9 |
Short-term bonds incl. CBs separate (KRW 100M) | 87.3 | 182.2 | 97.0 | 113.9 |
Current portion of LT debt separate (KRW 100M) | 43.1 | 42.4 | 42.3 | 0.2 |
Long-term borrowings separate (KRW 100M) | 0.2 | 0.6 | 0.2 | 0 |
Total debt separate (KRW 100M) | 130.6 | 225.2 | 149.5 | 139.0 |
Net debt separate (KRW 100M) | 86.0 | 144.8 | 91.3 | 7.2 |
Current liabilities separate (KRW 100M) | 217.6 | 318.7 | 245.4 | 225.4 |
Total liabilities separate (KRW 100M) | 218.9 | 324.9 | 253.6 | 228.6 |
Total equity separate (KRW 100M) | 253.0 | 132.8 | 222.0 | 251.0 |
Goodwill separate (KRW 100M) | 0 | 11.9 | 11.9 | 11.9 |
Goodwill and intangibles separate (KRW 100M) | 2.3 | 14.7 | 15.8 | 16.2 |
Investments in associates separate (KRW 100M) | 10.7 | 40.1 | 160.2 | 118.6 |
Investments in subsidiaries separate (KRW 100M) | 211.3 | 157.2 | 0 | 0 |
Working capital separate (KRW 100M) | -86.9 | -138.4 | -113.3 | -19.1 |
Retained earnings deficit separate (KRW 100M) | -729.6 | -906.2 | -905.2 | -969.2 |
Cash Flow (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow consolidated (KRW 100M) | -20 | -16 | -34 | 7 | 7 |
Dividends paid (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Instrument by Date
| Date | Instrument | Amount (KRW 100M) | Counterparty | Source |
|---|---|---|---|---|
2025 (Jun–Sep) | Rights offering (40.0M new shares) | ~116 | Shareholders; Humasis subscribed | Dealsite; Digital Today |
Mar–Apr 2026 | Third-party allotment (39,215,688 shares) | ~100 | Originally Supi Value-up / Supi Synergy funds; changed to Humasis on 9 Apr 2026 | Dealsite; Money Today |
2022–2026 | Multiple convertible bonds (four CBs on the corporate registry); repeated refixings | — | Including Kyungnam Pharm and Humasis | THE VC; Dealsite; Digital Today |
“—” = not publicly disclosed.
Financial Ratios (x) and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Current ratio separate (x) | 0.60 | 0.57 | 0.54 | 0.92 |
Debt to equity separate (x) | 0.52 | 1.70 | 0.67 | 0.55 |
Liabilities to equity separate (x) | 0.87 | 2.45 | 1.14 | 0.91 |
Equity to assets separate (%) | 53.6 | 29.0 | 46.7 | 52.3 |
Region Overview
| Region | Activity | Evidence |
|---|---|---|
Korea (domestic) | Overwhelming majority of revenue: domestic hygiene-product sales, artist management, Korean OTT and broadcast work, domestic concerts | Business descriptions; no export split disclosed |
Japan | Planned record-label partnership (stated Nov 2025); K-vocalist fan base | Money Today (Nov 2025) |
Asia (multi-country) | Nam Woo-hyun Asia tour announced Oct 2026 | MHN Sports via THE VC |
Global (historical) | Condom exports to WHO/UNFPA (1998); Kenya export contract | Wikipedia (Munhwa Ilbo) |
Global (OTT reach) | Newtopia: distributed via Coupang Play's global index (per company) | Money Today |
Valuation Multiples (KRW)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price adjusted (KRW) | 35,612 | 26,918 | 11,291 | 7,400 |
Year-end market cap (KRW 100M) | 483.5 | 385.2 | 192.7 | 238.7 |
Shares outstanding adjusted (10000 shares) | 142 | 149 | 178 | 323 |
Share Price & Returns
| Period | Start (adjusted, KRW) | End (KRW, 15 Oct 2026) | Return | Basis |
|---|---|---|---|---|
YTD 2026 | 7,400 (31 Dec 2025) | 2,900 | −60.8% | ValueLine |
~1 year | ~9,525 (2 Oct 2025 close of KRW 381 × 25) | 2,900 | ~−69.6% | Digital Today; analyst adjustment |
~3 years (from end-2023) | 26,918 | 2,900 | −89.2% | ValueLine |
~4 years (from end-2022) | 35,612 | 2,900 | −91.9% | ValueLine |
Valuation Multiples
| Multiple | Billions | Basis / comment |
|---|---|---|
P/E | n/m (loss-making); ValueLine shows −1.07x trailing | ValueLine |
P/B | 0.44x | Separate equity KRW 455.8 (100M), Jun 2026 |
EV / Sales | ~0.03x | EV ≈ market cap 202 + debt 125.8 − cash 242.8 − ST financial assets 57.8 ≈ 27.2; ÷ separate TTM revenue 245.8 × 0.25 adj. Unadjusted: 27.2 / 245.8 = 0.11x. Analyst-derived; excludes CB derivative liabilities and associate stakes. |
EV / EBITDA | ~2.1x | 27.2 / derived TTM EBITDA 13.0. Analyst-derived; low-quality EBITDA. |
Analyst Conclusions
Management guidance: none published. Consensus growth expectations: none.
Bull Case
-
Operations are close to break-even and the balance sheet is now net cash. Separate TTM operating income turned positive in 2026. At 1H 2026 the parent held ~KRW 30bn in cash and short-term financial assets against ~KRW 12.6bn of debt. With market cap at ~0.44x book, a sustained operating profit could drive a re-rating.
-
Roster depth with near-term monetisation catalysts. Q4 2026 brings the Nam Woo-hyun LP and Asia tour, Jung Eun-ji's solo activity, Lee Jun-young's post-Four Hands demand, and new veteran signings. Billions Plus offers production upside on OTT.
-
A financially stronger owner. Stella PE's group package includes Humasis, which reportedly holds more than KRW 200bn in cash. That reduces funding risk and opens potential for asset injections or strategic deals. The Tris stake ties Billions to an aerospace narrative with a contract running to 2039.
Bear Case
-
The equity story is serially dilutive. Shares outstanding went from 40.7M (mid-2025) to more than 119M pre-consolidation equivalent within a year. Two 5:1 consolidations then followed. A 1H 2026 derivative loss of ~KRW 15bn shows the CB overhang remains costly.
-
Below-the-line losses persist structurally. Interest of ~KRW 2.5bn a year and associate losses of ~KRW 2–2.6bn a year exceed operating EBITDA of ~KRW 1.0–1.3bn. Net losses therefore continue even at operating break-even.
-
Strategic drift and governance risk. Four identities in nine years, a controversial signing and minority-shareholder disputes at the parent suggest capital allocation may be driven by group or theme considerations rather than shareholder returns in the listed entity.
Key Catalysts and Monitorables (next 12 months)
| Item | What to watch |
|---|---|
| Q3 2026 quarterly report (expected ~mid-Nov 2026) | Whether separate operating income stays positive; size of CB derivative remeasurement |
| Share price vs. KRW 1,000 threshold | Already at ~KRW 2,900; another collapse would revive delisting risk |
| CB conversions / refixings | Remaining CB balance (KRW 100.9 (100M) at Jun-2026) and new issuance |
| Stella PE group restructuring | Asset transfers, mergers or sale of Billions or Kyungnam Pharm stakes |
| New CEO Kim Ki-heung's strategy | First public strategy articulation; board composition disclosure |
| Artist pipeline | Yoo Ah-in's Vampir reception; Q4 2026 concerts and tours; Japan label deal |
| Tris investment | Follow-on investments or a broader aerospace/advanced-manufacturing move |
| FY2026 annual report (Mar 2027) | Audit opinion, going-concern language, segment disclosure |
Analyst Verdict
Billions Co., Ltd. is not the NFT company named in the request list. It is the latest incarnation of the 1973 Seohung/Unidus latex-rubber business, and since 2023 its identity has been anchored in talent management. The investment case rests less on the condom-and-gloves franchise than on three questions: whether the entertainment roster can become a self-funding operating business, whether the capital structure has finally been reset, and how the new controlling owner, Stella PE, intends to use the group.
The data support a guarded improvement at the operating line. Consolidated operating losses narrowed from KRW 5.6bn (FY2021) to KRW 0.8bn (FY2025), and separate TTM operating income was marginally positive in 2026. The parent's balance sheet now shows net cash and equity of ~KRW 45.6bn. These are not trivial gains.
But the improvement has been bought with shareholder capital: a 2025 par reduction, roughly KRW 21.6bn of parent-funded equity in a year, and two consecutive 5:1 consolidations to avoid low-price delisting. Meanwhile, net income remains deeply negative because of CB interest, derivative remeasurement and associate losses. The 1H 2026 TTM separate net loss of KRW 18.9bn is roughly three-quarters of annual revenue. The accumulated deficit of ~KRW 97bn dwarfs the business's earnings capacity.
The valuation looks optically cheap, at 0.44x P/B and an EV near KRW 2.7bn. That cheapness reflects the market's scepticism about capital allocation in a listed vehicle that has repeatedly reinvented itself around market themes. The disclosure gaps should themselves be treated as a risk factor: no segment or geographic data, an unidentified auditor and board in the sources reviewed, and stale officer data across aggregators.
**Verdict: high-risk, special-situation exposure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Age | Source |
|---|---|---|---|---|---|
Kim Ki-heung (김기흥) | Representative Director (CEO) | Registered 14 Sep 2026 | — | — | THE VC; Bolta; JobKorea |
Park Jong-jin (박종진) | Former Co-CEO, then sole CEO | Until ~Sep 2026 | — | — | JobKorea; Butler; Wikipedia |
Shim Hwa-seok (심화석) | Former Co-CEO | From Jul 2023 to ~2026 | Held 3.76% of special securities (Aug 2025) | — | Wikipedia; Digital Today |
Hong Sang-hyuk (홍상혁) | Former Co-CEO (Blueberry NFT era); CEO of Blueberry Meta | ~2021–2023 | Liveplex; Mobile One Communication | — | Edaily; The Value News |
Oh Sung-won (오성원) | Former Co-CEO (Blueberry NFT era) | ~2021–2022 | Liveplex; Massive Marketing | — | Edaily |
Kim Sung-hoon (김성훈) | Former CEO and largest shareholder (Unidus) | Until 2017 | Unidus | Born 1967 (Statbase) | Edaily; Statbase |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
Jul 2023 | Shim Hwa-seok appointed CEO | Coincided with the J-Flex acquisition | Wikipedia |
2024–2026 | Co-CEO structure (Park Jong-jin and Shim Hwa-seok); earlier Hong Sang-hyuk and Shim Hwa-seok | Post-Humasis acquisition | JobKorea |
| 2026 | Changed to Park Jong-jin as sole CEO | Shim Hwa-seok departure | Butler; JobKorea |
31 Mar 2026 | AGM board reshuffle | Followed the Stella PE takeover of Mirae I&G | THE VC registry; The Bell |
14 Sep 2026 | Kim Ki-heung registered as CEO | Second wave of post-Stella changes | THE VC registry |
Major Shareholders
| Holder | Stake | Basis / date | Source |
|---|---|---|---|
Humasis Co., Ltd. and 3 related parties | 57.12% (3,798,271 shares, post-consolidation) | 5% report, 4 Sep 2026 | TokenPost |
— of which Digital Bridge New Technology Investment Association | 5,377,945 pre-consolidation shares (~1.08M post), bought off-market at KRW 1,352 on 11 May 2026 | Added as Humasis related party, 18 May 2026 | Butler (DART feed) |
Kyungnam Pharm (via CB holdings) | 18.2% of special securities (Oct 2025); current not disclosed | Cross-holding | Digital Today |
Former CEO Shim Hwa-seok | 3.76% of special securities (Aug 2025) | Current not disclosed | Digital Today |
Institutional investors (top 10) | Not disclosed; no meaningful institutional ownership identified | — | — |
Free float (estimated) | ~43% by subtraction (100% − 57.12%), before CB dilution | Analyst estimate | Derived |
Competitive Landscape
Key Competitors
| Competitor | Listing | Positioning vs. Billions | Source for identification |
|---|---|---|---|
Fantagio | KOSDAQ (group affiliate) | Actor/idol agency of similar scale (~97 employees vs. Billions ~86) | THE VC peer set |
Mystic Story | Private | Music and actor management (~77 employees) | THE VC |
P Nation | Private | Music-focused agency | THE VC |
Big Ocean ENM | Private | Management | THE VC |
Sublime | Private | Actor/creator management | THE VC |
Blitzway Entertainment | KOSDAQ | Figures plus actor management; similar pivot from another core business | Asia Economy |
KeyEast | KOSDAQ | Actor management, larger scale | Analyst identification |
IHQ | KOSDAQ | Actor management and broadcasting | Analyst identification |
Management SOOP / BH Entertainment / Kakao Ent. actor labels | Private / subsidiaries | Top-tier actor agencies with larger rosters and capital | Analyst identification |
Peer Comparison FY2025
| Metric | Billions (FY2025) | Fantagio |
|---|---|---|
Revenue (KRW 100M) | 253 (consolidated) | — |
Revenue growth (%) | -39.3 | — |
Operating margin (%) | -3.2 | — |
Employees | ~86 (Aug 2026) | 97 (Aug 2026) |



